Navigation Links
ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia
Date:9/30/2011

EXTON, Pa., Sept. 30, 2011 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced the license of worldwide rights from Intellect Neurosciences, Inc. (OTCBB: ILNS) to its clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia (FA), a rare, hereditary, progressive neurodegenerative disease.

OX1, or indole-3-propionic acid (IPA), is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against neurodegenerative disease.  In a recent Phase 1 safety and tolerability study conducted in the Netherlands, OX1 was demonstrated to be safe and well tolerated at all dose levels tested. ViroPharma expects to initiate a phase 2 study within 12 to 18 months after completion of longer term toxicology studies. ViroPharma intends to file for Orphan Drug Designation upon review of the phase 2 proof of concept data.

Under the terms of the agreement, ViroPharma has exclusive worldwide rights to develop and commercialize OX1 for the treatment, management or prevention of any disease or condition covered by Intellect's patents. ViroPharma paid Intellect Neurosciences a $6.5 million up-front licensing fee and will pay additional milestones based upon defined events.  The maximum of these milestone payments assuming successful advancement to market could amount to $120 million. The company will also pay a tiered royalty of up to a maximum percentage of low teens, based on annual net sales.

"The mission of ViroPharma is to improve the health of patients suffering from serious diseases and unmet medical needs, and Friedreich's Ataxia clearly fits in that class," said Vincent Milano, ViroPharma's chief executive officer.  "FA robs children and young adults of muscle coordination leading to loss of mobility, energy, speech, and hearing, and presents a significant risk of diabetes an
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ViroPharma Announces Additional Securities Repurchase Program
2. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
3. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
4. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
5. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
6. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
7. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
8. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
9. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
10. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
11. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
(Date:8/19/2014)... BIRMINGHAM, Ala. , Aug. 19, 2014  The Alabama ... re-affirmed that patients can sue drug makers who mislead doctors ... cause harmful side‑effects.  The case is Weeks v. Wyeth, and ... drug makers in that same case last year. Heninger Garrison ... represent the patient in the case, Danny Weeks ...
(Date:8/19/2014)... -- Minimally Invasive Devices Inc. (MID), a ... that Mitsubishi Corporation has formally agreed to exclusively distribute ... Japan . MID anticipates that FloShield will ... in the second half of 2015. ... Storz GMBH & Co. (endoscopic instruments and devices) in ...
Breaking Medicine Technology:Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2
... achieve undetectable viral load in Phase,IIa trial within ... care, SAN FRANCISCO, Nov. 1 New ... protease inhibitor (PI) being,developed by Tibotec BVBA for ... Tibotec will present findings from three TMC435 studies,including ...
... Higher Sustained Virological Response Rates Recognized as Marker ... 1 A new,independently-conducted study being presented at ... the Study of Liver Diseases (AASLD) shows that,PEGASYS(R) ... response (SVR) rates for hepatitis C patients as,compared ...
Cached Medicine Technology:Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 2Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 3Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 4Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7
(Date:8/20/2014)... 20, 2014 Inc. Magazine recently ... its 33rd annual Inc. 500|5000, an exclusive ranking ... represents the most comprehensive look at the most ... such as Yelp, Pandora, Timberland, Dell, Domino’s Pizza, ... early exposure as members of the Inc. 500|5000. ...
(Date:8/20/2014)... 2014 Building on growing success ... predicted stage iii and iv pressure ulcers with ... approached 90%. A company spokesperson commented that these ... or academic settings. The resulting capabilities can be ... hospital-acquired conditions to help providers avoid financial losses ...
(Date:8/20/2014)... 2014 Ticketability.com has Theresa ... fair prices. The well-known medium has been thrilling many ... touring in 19 cities, with tickets becoming available August ... will visit are Albany, Baltimore, Trenton, Erie, Buffalo, Philadelphia, ... Hills and San Diego. The medium’s fans can obtain ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Blaine ... the innovative RevitaDERM® Psoriasis Treatment to ... associated with psoriasis. This all-in-one product was created ... RevitaDERM® Psoriasis Treatment is powered by coal tar ... associated with this effective ingredient. , RevitaDERM® ...
(Date:8/20/2014)... The “Human Insulin Market by Product Type ... Human Insulin (Rapid Acting, Long Acting, Premixed)], by ... - Forecast to 2019” provides a detailed overview ... trends,and strategies impacting the global human insulin market ... revenue and share analysis. , Browse 110 market ...
Breaking Medicine News(10 mins):Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 2Health News:Etransmedia Makes Exclusive List for the Eighth Consecutive Year in Inc. Magazine 3Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2Health News:RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4
... Georgia Center for Biotechnology and Genomic Medicine has been selected ... of children involved in a worldwide study of the causes ... in the mammoth study that will eventually follow 8,000 at-risk ... collecting blood every three months as they go. , ...
... Bulletin,Board: DSCI), a provider of advanced wound care products, ... its agency for investor relations and,corporate communications., "Derma ... in part to our,recent acquisition of the first aid ... our MEDIHONEY(TM) products, and the licensing of DSC127, a,novel ...
... is the,most significant advancement in surgical medicine in ... variety of academic and private hospitals around,the world, ... globally. Despite the fact that both StomaphyX(TM) and,EsophyX(TM) ... U.S. centers,have already been trained to perform these ...
... ATLANTA, December 17, 2007A new American Cancer Society report ... cancer cases and 7.6 million cancer deaths (about 20,000 ... comes from the first-ever Global Cancer Facts & Figures, ... of Facts & Figures publications. The report estimates that ...
... with a team at the University of California, San ... affects a childs risk of getting Kawasaki disease (KD), ... throughout the body. The genetic variation influences immune ... as the risk of developing coronary artery aneurysms ...
... activities that stretch youngsters, creativity and forge bonds with ... -- When you,re Christmas shopping for toys, ignore the ... healthy childhood development and reinforce personal relationships. , "It,s ... imagination, manipulation, and change. If a toy is static ...
Cached Medicine News:Health News:MCG selected as RNA laboratory for worldwide diabetes study 2Health News:Derma Sciences Inc Selects Allen & Caron for Investor Relations and Corporate Communications 2Health News:Derma Sciences Inc Selects Allen & Caron for Investor Relations and Corporate Communications 3Health News:EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures 2Health News:EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures 3Health News:EndoGastric Solutions Opens Three Training Centers to Keep Up with Demand from Surgeons Wanting to Learn StomaphyX(TM) Procedures 4Health News:New report estimates 12 million cancer deaths worldwide 2Health News:International research collaboration narrows focus on genetic cause of Kawasaki disease 2Health News:International research collaboration narrows focus on genetic cause of Kawasaki disease 3Health News:Picking the Right Toys Isn't Child's Play 2
Quantel Medical introduces the new Aviso A/B, a new generation high definition ultrasound system in a unique laptop or desktop PC workstation....
... is the result of years of research ... innovation and value, continues to bring you ... CT 200 is faster and easier to ... The CT 200 is the latest innovation ...
The Excel Series from DGH-KOI is an excellent choice for the ophthalmic surgeon performing cataract and other general ophthalmic procedures. With a broad range of blade options and our special Excel ...
New! Visually superior, micrometer handle, single foot plate, blade extends to 3.0 mm....
Medicine Products: